Literature DB >> 19656692

Response to sequential treatment schedules in childhood epilepsy: risk for development of refractory epilepsy.

J Ramos-Lizana1, P Aguilera-López, J Aguirre-Rodríguez, E Cassinello-García.   

Abstract

PURPOSE: To investigate response to sequential treatment schedules and risk of development of refractory epilepsy in childhood.
METHODS: All children younger than 14 years with two or more unprovoked seizures seen at our hospital between 1994 and 2004 were included and prospectively followed. "Seizure control" was defined as a 2-year seizure-free interval without further recurrences except those related to attempts of medication withdrawal and "refractory epilepsy" as failure of >2 drugs plus >1 seizure/month for > or =18 months.
RESULTS: 343 Patients were included, 191 males and 152 females. Mean age at diagnosis was 4y 10 mo (SD 3 year 10 month). Mean follow-up period was 76.2 mo (SD 35.2). The probability of achieving "seizure control" was 70% and 86% at 5 and 10 years. 59% of patients were "controlled" with the first drug used. Among patients failing the first, second and third therapeutic regimen due to lack of efficacy, 39%, 23% and 12% respectively were finally "controlled" with subsequent treatment schedules Risk of development of refractory epilepsy was 8% and 12% at 6 and 10 years.
CONCLUSION: After failing a first drug, a significant proportion of children can still be controlled with subsequent therapeutic schedules. Only a small proportion develops refractory epilepsy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656692     DOI: 10.1016/j.seizure.2009.07.001

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

1.  Current Principles in the Management of Drug-Resistant Epilepsy.

Authors:  Nathan A Shlobin; Josemir W Sander
Journal:  CNS Drugs       Date:  2022-05-20       Impact factor: 6.497

Review 2.  Refractory epilepsy in children.

Authors:  Satinder Aneja; Puneet Jain
Journal:  Indian J Pediatr       Date:  2014-08-09       Impact factor: 1.967

3.  Second monotherapy in childhood absence epilepsy.

Authors:  Avital Cnaan; Shlomo Shinnar; Ravindra Arya; Peter C Adamson; Peggy O Clark; Dennis Dlugos; Deborah G Hirtz; David Masur; Tracy A Glauser
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

4.  Subgroup analysis of seizure and cognitive outcome after vagal nerve stimulator implantation in children.

Authors:  Corine Knorr; Ladina Greuter; Shlomi Constantini; Itzhak Fried; Uri Kremer; Alexandre N Datta; Raphael Guzman; Jehuda Soleman
Journal:  Childs Nerv Syst       Date:  2020-05-02       Impact factor: 1.532

5.  NMR-based metabolomics in pediatric drug resistant epilepsy - preliminary results.

Authors:  Łukasz Boguszewicz; Ewa Jamroz; Mateusz Ciszek; Ewa Emich-Widera; Marek Kijonka; Tomasz Banasik; Agnieszka Skorupa; Maria Sokół
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

6.  Specific safety and tolerability considerations in the use of anticonvulsant medications in children.

Authors:  Amy Z Crepeau; Brian D Moseley; Elaine C Wirrell
Journal:  Drug Healthc Patient Saf       Date:  2012-06-06

7.  Clinical Prediction Rule of Drug Resistant Epilepsy in Children.

Authors:  Pairoj Boonluksiri; Anannit Visuthibhan; Kamornwan Katanyuwong
Journal:  J Epilepsy Res       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.